NPPB and type 2 diabetes mellitus: HFrEF patients who were prescribed an SGLT2i were also more likely to have T2DM (62.7 % vs. 45.1 %, p = 0.0191) and have a higher eGFR and BNP with a lower LVEF at baseline (60.51 vs. 54.41, p = 0.0472, 1507.04 vs. 1189.87, p = 0.035, 18.86 vs. 24.72, p = 0.003).